Last reviewed · How we verify
NCT05483036
Perception in Parkinson's Disease
trial in Parkinson's Disease in 54 participants. Completed in 1 May 2025.
1 May 2025
Quick facts
| Lead sponsor | Boston University Charles River Campus |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 54 |
| Start date | 1 September 2022 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 May 2025 |
| Sites | 1 location across United States |
Conditions studied
- Parkinson's Disease — all drugs for Parkinson's Disease →
- Perception — all drugs for Perception →
- Visual Hallucination — all drugs for Visual Hallucination →
Sponsor
Boston University Charles River Campus
Who can join
Adults 40 to 110, any sex, with Parkinson's Disease or Perception. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators plan to examine the relation of perceptual variables-basic vision, unusual perceptual experiences(including but not limited to visual hallucinations)-to relevant functional variables such as cognition, mood, and alertness/sleepiness in an online sample of persons with Parkinson's disease (PwPD). It is hypothesized that unusual perceptual experiences will relate significantly to the selected variables. Participants do not need to experience visual hallucinations to be able to participate in this study. This is an observational study only, and not an interventional study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05483036
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson's Disease
Currently open trials in the same condition.
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
- NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
- NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
- NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting
Other Boston University Charles River Campus trials
Trials by the same sponsor.
- NCT07461584 — Memory Enhancement in Aging With Optimal Dosing · EARLY_PHASE1 · not yet recruiting
- NCT07208318 — Restructuring the Alpha-Gamma Code in Aging Vision · EARLY_PHASE1 · not yet recruiting
- NCT06182241 — Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South · NA · not yet recruiting
- NCT07158801 — Project EMPOWER-OCD · Phase 1 · not yet recruiting
- NCT05624931 — Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Town, South Africa · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05483036 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston University Charles River Campus
- Last refreshed: 19 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483036.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing